NCT02039791View on ClinicalTrials.gov

Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 30, 2016

Study Completion Date

August 31, 2016

Conditions
Cervical Cancer
Interventions
BIOLOGICAL

Nimotuzumab

200mg/w,weekly, 6 weeks

DRUG

Carboplatin

AUC 6, d1，1 cycle/21d, 2 cycles

DRUG

Paclitaxel

"175 mg/m2, d1~1 cycle/21d, 2 cycles."

Trial Locations (1)

200080

Shanghai first people's hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Biotech Pharmaceutical Co., Ltd.

OTHER